Abstract
Aim
The purpose of this study was to investigate the co-expression of survivin, c-erbB2, and COX-2 in endometrial cancer tissues and evaluate its prognostic significance in endometrial cancer
Methods
Tumor tissue biopsies from 110 patients with primary untreated endometrial carcinomas were studied by immunohistochemistry. Statistical analysis evaluated correlation of antigen expression with tumor stage, grade, myometrial invasion, and histologic type. Association with disease outcome was also investigated
Results
The results showed that expression of the three antigens was independently associated with histological grade, disease stage, and myometrial invasion. Clinicopathological parameters were also associated with the number of antigens expressed by each tumor, the expression of more antigens correlating with advanced stage disease and deep myometrial invasion. In a 10-year follow-up, patients with tumors expressing more of these three antigens had significantly lower survival rate that those with smaller expression score
Conclusions
Our results indicate that the co-expression score has independent prognostic value for endometrial cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ai Z, Yin L, Zhou X et al (2006) Inhibition of survivin reduces cell proliferation and induces apoptosis in human endometrial cancer. Cancer 107:746–756. doi:10.1002/cncr.22044
Berchuck A, Rodriguez G, Kinney RB et al (1991) Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease. Am J Obstet Gynecol 164:15–21
Bezwoda WR (2000) c-erb-B2 expression and response to treatment in metastatic breast cancer. Med Oncol 17:22–28. doi:10.1007/BF02826212
Bhatavdekar JM, Patel DD, Shah NG et al (2000) Prognostic significance of immunohistochemically localized biomarkers in stage II and stage III breast cancer: a multivariate analysis. Ann Surg Oncol 7:305–311. doi:10.1007/s10434-000-0305-5
Cherchi PL, Marras V, Capobianco G et al (2001) Prognostic value of p53, c-erb-B2 and MIB-1 in endometrial carcinoma. Eur J Gynaecol Oncol 22:451–453
Erkanli S, Kayaselcuk F, Kuscu E et al (2006) Expression of survivin, PTEN and p27 in normal, hyperplastic, and carcinomatous endometrium. Int J Gynecol Cancer 16:1412–1418. doi:10.1111/j.1525-1438.2006.00541.x
Erkanli S, Bolat F, Kayaselcuk F, Demirhan B, Kuscu E (2007) COX-2 and survivin are overexpressed and positively correlated in endometrial carcinoma. Gynecol Oncol 104:320–325. doi:10.1016/j.ygyno.2006.08.044
Ferrandina G, Legge F, Ranelletti FO et al (2002) Cyclooxygenase-2 expression in endometrial carcinoma: correlation with clinicopathologic parameters and clinical outcome. Cancer 95:801–807. doi:10.1002/cncr.10736
Ferrandina G, Ranelletti FO, Gallotta V et al (2005) Expression of cyclooxygenase-2 (COX-2), receptors for estrogen (ER), and progesterone (PR), p53, ki67, and neu protein in endometrial cancer. Gynecol Oncol 98:383–389. doi:10.1016/j.ygyno.2005.04.024
Fowler JM, Ramirez N, DE Cohn et al (2005) Correlation of cyclooxygenase-2 (COX-2) and aromatase expression in human endometrial cancer: tissue microarray analysis. Am J Obstet Gynecol 192:1262–1271. doi:10.1016/j.ajog.2005.01.009 discussion 1271-1263
Fujiwaki R, Iida K, Kanasaki H et al (2002) Cyclooxygenase-2 expression in endometrial cancer: correlation with microvessel count and expression of vascular endothelial growth factor and thymidine phosphorylase. Hum Pathol 33:213–219. doi:10.1053/hupa.2002.31292
Hernandez E (2001) Endometrial adenocarcinoma: a primer for the generalist. Obstet Gynecol Clin North Am 28:743–757. doi:10.1016/S0889-8545(05)70233-3
Horvai AE, Li L, Xu Z et al (2003) Malignant mesothelioma does not demonstrate overexpression or gene amplification despite cytoplasmic immunohistochemical staining for c-Erb-B2. Arch Pathol Lab Med 127:465–469
Karahan N, Guney M, Baspinar S et al (2007) Expression of gelatinase (MMP-2 and MMP-9) and cyclooxygenase-2 (COX-2) in endometrial carcinoma. Eur J Gynaecol Oncol 28:184–188
Kuesters S, Maurer M, Burger AM, Metz T, Fiebig HH (2006) Correlation of ErbB2 gene status, mRNA and protein expression in a panel of >100 human tumor xenografts of different origin. Onkologie 29:249–256. doi:10.1159/000093048
Lambropoulou M, Alexiadis G, Limberis V, Nikolettos N, Tripsianis G (2005) Clinicopathologic and prognostic significance of cyclooxygenase-2 expression in endometrial carcinoma. Histol Histopathol 20:753–759
Lambropoulou M, Stefanou D, Alexiadis G et al (2007) Cytoplasmic expression of c-erb-B2 in endometrial carcinomas. Onkologie 30:495–500. doi:10.1159/000107734
Lehner R, Enomoto T, McGregor JA et al (2002) Correlation of survivin mRNA detection with histologic diagnosis in normal endometrium and endometrial carcinoma. Acta Obstet Gynecol Scand 81:162–167. doi:10.1034/j.1600-0412.2002.810213.x
Markogiannakis E, Georgoulias V, Margioris AN et al (1997) Estrogens and glucocorticoids induce the expression of c-erbB2/NEU receptor in Ishikawa human endometrial cells. Life Sci 61:1083–1095. doi:10.1016/S0024-3205(97)00617-6
Ohno S, Ohno Y, Suzuki N et al (2005) Multiple roles of cyclooxygenase-2 in endometrial cancer. Anticancer Res 25:3679–3687
Pallares J, Martinez-Guitarte JL, Dolcet X et al (2005) Survivin expression in endometrial carcinoma: a tissue microarray study with correlation with PTEN and STAT-3. Int J Gynecol Pathol 24:247–253. doi:10.1097/01.pgp.0000163849.37129.d4
Pappa KI, Anagnou NP (2005) Emerging issues of the expression profiling technologies for the study of gynecologic cancer. Am J Obstet Gynecol 193:908–918. doi:10.1016/j.ajog.2005.01.018
Prat J, Oliva E, Lerma E, Matias-Guiu X (1994) Uterine papillary serous adenocarcinoma. A 10-case study of p53 and c-erbB-2 expression and DNA content. Cancer 74:1778–1783. doi:10.1002/1097-0142(19940915)74:6<1778:AID-CNCR2820740621>3.0.CO;2-5
Smid-Koopman E, Blok LJ, Helmerhorst TJ et al (2004) Gene expression profiling in human endometrial cancer tissue samples: utility and diagnostic value. Gynecol Oncol 93:292–300. doi:10.1016/j.ygyno.2004.01.022
Takai N, Miyazaki T, Nishida M, Nasu K, Miyakawa I (2002) Survivin expression correlates with clinical stage, histological grade, invasive behavior and survival rate in endometrial carcinoma. Cancer Lett 184:105–116. doi:10.1016/S0304-3835(02)00190-8
Acknowledgment
We thank Professor E. Sivridis for eagerly providing the material for this study and the facilities of the Department of Pathology, Democritus University of Thrace.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lambropoulou, M., Papadopoulos, N., Tripsianis, G. et al. Co-expression of survivin, c-erbB2, and cyclooxygenase-2 (COX-2): prognostic value and survival of endometrial cancer patients. J Cancer Res Clin Oncol 136, 427–435 (2010). https://doi.org/10.1007/s00432-009-0673-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-009-0673-6